ALK inhibitor

DRUG4 trials

Sponsors

Ayumu Arakawa Department of Pediatric Oncology, National Cancer Center Hospital, Shanghai Changzheng Hospital, Chinese Academy of Medical Sciences, Suzhou Genhouse Bio Co., Ltd.

Conditions

Advanced Solid Tumor With Oncogenic Driver MutationsColorectal CancerFISH Identified ALK Fusion Positive or NegativePatients With Advanced Solid TumorPediatric refractory malignant solid tumors, Pediatric malignant lymphoma malignant solid tumors,malignant lymphomaUntreated Advanced NSCLC Patients

Phase 1

Phase I trial of alectinib in pediatric patients with malignant solid tumors or malignant lymphoma(NCCH1708)

Active, not recruitingJPRN-jRCT2091220354

Ayumu Arakawa Department of Pediatric Oncology, National Cancer Center HospitalPediatric refractory malignant solid tumors, Pediatric malignant lymphoma malignant solid tumors,malignant lymphoma

Start: 2018-06-19Target: 12Updated: 2025-07-18

Phase 2

A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors

RecruitingNCT06322095

Suzhou Genhouse Bio Co., Ltd.Advanced Solid Tumor With Oncogenic Driver Mutations, Patients With Advanced Solid Tumor

Start: 2024-03-22End: 2025-12-31Target: 72Updated: 2024-10-01

Unknown Phase

ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.

Shanghai Changzheng HospitalColorectal Cancer

Start: 2019-03-01End: 2021-03-01Target: 30Updated: 2019-02-15

The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring

Chinese Academy of Medical SciencesFISH Identified ALK Fusion Positive or Negative, Untreated Advanced NSCLC Patients

Start: 2020-08-01End: 2025-03-31Target: 75Updated: 2020-08-05